Angiotensin Receptor Blockers in Diabetic Nephropathy

Overview

Journal Curr Diab Rep

Publisher Current Science

Specialty Endocrinology

Date 2003 Mar 20

PMID 12643209

Authors

D A Price

N K Hollenberg

Affiliations

Soon will be listed here.

Abstract

Where shall we place angiotensin receptor blockers in the scheme of the prevention of diabetic nephropathy? Only the results of a large, randomized double-blind trial with a comparable and appropriate alternative would prove therapeutic efficacy. The results of several trials with angiotensin-converting enzyme (ACE) inhibitors have proven them to be the standard of care for diabetics and their kidneys. As reviewed in this article, the results of three large such clinical trials have recently been completed with angiotensin receptor blockers in patients with type 2 diabetes mellitus. Initial results appear favorable. However, whether angiotensin blockers have more to offer than ACE inhibitors is still speculative. The renin-angiotensin system plays an important role in the pathogenesis of diabetic nephropathy. Since alternative pathways to ACE have been uncovered in the formation of angiotensin II, inhibition at the final end point would provide favored blockade. Because angiotensin receptor blockers do provide this specific blockade, they offer far more promise than ACE inhibitors.

References

Gansevoort R, de Zeeuw D, de Jong P . Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?. Kidney Int. 1994; 45(3):861-7. DOI: 10.1038/ki.1994.113. View

Christlieb A, Kaldany A, DElia J . Plasma renin activity and hypertension in diabetes mellitus. Diabetes. 1976; 25(10):969-74. DOI: 10.2337/diab.25.10.969. View

Ravid M, Lang R, Rachmani R, Lishner M . Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med. 1996; 156(3):286-9. View

Parving H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345(12):870-8. DOI: 10.1056/NEJMoa011489. View

Chan J, Critchley J, Tomlinson B, Chan T, Cockram C . Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol. 1997; 17(1):72-80. DOI: 10.1159/000169075. View

Ruilope L . Renoprotection and renin-angiotensin system blockade in diabetes mellitus. Am J Hypertens. 1998; 10(12 Pt 2):325S-331S. DOI: 10.1016/s0895-7061(97)00390-7. View

Fisher N, Hollenberg N . Renal vascular responses to renin inhibition with zankiren in men. Clin Pharmacol Ther. 1995; 57(3):342-8. DOI: 10.1016/0009-9236(95)90160-4. View

Wolf G, Ziyadeh F . The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis. 1997; 29(1):153-63. DOI: 10.1016/s0272-6386(97)90023-8. View

Perez G, Lespier L, Jacobi J, Oster J, KATZ F, VAAMONDE C . Hyporeninemia and hypoaldosteronism in diabetes mellitus. Arch Intern Med. 1977; 137(7):852-5. View

10.

Zhou A, Yu L, Li J, Zhang J, Wang H . Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor. Hypertens Res. 2000; 23(4):391-7. DOI: 10.1291/hypres.23.391. View

11.

Ingelfinger J, Zuo W, Fon E, Ellison K, Dzau V . In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest. 1990; 85(2):417-23. PMC: 296440. DOI: 10.1172/JCI114454. View

12.

Burns K . Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis. 2000; 36(3):449-67. DOI: 10.1053/ajkd.2000.16192. View

13.

Lansang M, Hollenberg N . ACE inhibition and the kidney: species variation in the mechanisms responsible for the renal haemodynamic response. J Renin Angiotensin Aldosterone Syst. 2002; 1(2):119-24. DOI: 10.3317/jraas.2000.013. View

14.

Moore T, Crantz F, Hollenberg N, Koletsky R, LeBoff M, Swartz S . Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension. 1981; 3(2):168-73. DOI: 10.1161/01.hyp.3.2.168. View

15.

Lafayette R, Mayer G, Park S, Meyer T . Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1992; 90(3):766-71. PMC: 329928. DOI: 10.1172/JCI115949. View

16.

Meggs L, Katzberg R, DeLeeuw P, Hollenberg N . Specific desensitization of the canine renal vasculature to angiotensin II despite cyclo-oxygenase inhibition. Yale J Biol Med. 1985; 58(5):453-8. PMC: 2589940. View

17.

Cooper M, Gilbert R, Epstein M . Pathophysiology of diabetic nephropathy. Metabolism. 1998; 47(12 Suppl 1):3-6. DOI: 10.1016/s0026-0495(98)90362-6. View

18.

Gordon M, Price D, Hollenberg N . Blunted suppression of plasma renin activity in diabetes. J Renin Angiotensin Aldosterone Syst. 2002; 1(3):252-6. DOI: 10.3317/jraas.2000.038. View

19.

Johns E, Murdock R, Singer B . The effect of angiotensin I converting enzyme inhibitor (SQ 20881) on the release of prostaglandins by rabbit kidney, in vivo. Br J Pharmacol. 1977; 60(4):573-81. PMC: 1667381. DOI: 10.1111/j.1476-5381.1977.tb07537.x. View

20.

Price D, DeOliveira J, Fisher N, Hollenberg N . Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension. 1997; 30(2 Pt 1):240-6. DOI: 10.1161/01.hyp.30.2.240. View